Once Rumored, Now Real: Torchy’s Tacos Offers Exclusive Gold Card in Annual Holiday Gift Card Celebration
AUSTIN, Texas–(BUSINESS WIRE)–Torchy’s Tacos is inviting Taco Junkies everywhere to turn their naughty into nice with their annual Holiday Gift Card... Read more.
‘Tis the Season for NEW Holiday Cocktails at Applebee’s
Applebee’s Sleigh Bell Sips include two $5 limited-time Mucho Cocktails™ and $6 Stella Artois draft beer PASADENA, Calif.–(BUSINESS WIRE)–Tis the... Read more.
HEINZ® and World-Renowned Chef Marcus Samuelsson Elevate Up-and-Coming Black Chefs with New ‘Open Kitchen’ Series
The newest program from the HEINZ® Black Kitchen Initiative serves up top restaurant takeovers PITTSBURGH & CHICAGO–(BUSINESS WIRE)–HEINZ® announces... Read more.
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
– Initial SOLSTICE data suggests the potential of VIR-3434 + VIR-2218 to address the unmet need for a highly efficacious hepatitis delta therapy – – New MARCH... Read more.
GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative
GSK launches Mapping Myelofibrosis to help chart course for those affected by the disease. Myelofibrosis is a complex blood cancer that impacts nearly 25,000 people... Read more.
Core & Main Added to the S&P MidCap 400® Index
ST. LOUIS–(BUSINESS WIRE)–Core & Main Inc. (NYSE: CNM), a leader in advancing reliable infrastructure with local service, nationwide, today announced... Read more.
Creative Media & Community Trust Announces Date for Its Third Quarter 2023 Earnings Release and Conference Call
LOS ANGELES–(BUSINESS WIRE)–Creative Media & Community Trust (NASDAQ: CMCT; TASE: CMCT) (“CMCT”) announced today that it will report its third... Read more.
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneous injectable... Read more.
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001
Alzamend’s recently completed Phase IIA Study of AL001 in Alzheimer’s patients and healthy subjects showed a benign safety profile and identified a candidate... Read more.
Zuora Announces Date for Its Third Quarter Fiscal 2024 Earnings Conference Call
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Zuora (NYSE: ZUO), a leading monetization suite for modern businesses, today announced that it will report financial... Read more.